← All trials
NCT00891176
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2009
- Primary completion
- Oct 1, 2012
- Completion date
- Nov 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 582
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- menitorix
- menitorix
- pneumococcal 13-valent conjugate vaccine
- glyco-conjugate neisseria meningitidis serogroup c vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- pneumococcal 7-valent conjugate vaccine
- pneumococcal 7-valent conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- Monovalent group C meningococcal vaccine
- Inactivated polio virus - Enhanced
- Inactivated polio virus - Enhanced
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.